EU Approves Datroway as 1L Monotherapy in PD‑1/PD‑L1–Ineligible Metastatic TNBC After TROPION‑Breast02 Survival Gain
- Badari Andukuri
- 20 minutes ago
- 2 min read
AstraZeneca and Daiichi Sankyo have secured European Commission approval for Datroway (datopotamab deruxtecan) as a first-line monotherapy for adult patients diagnosed with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor treatments.
This regulatory milestone follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Also read: UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
The clinical authorization is grounded in results from the Phase III TROPION-Breast02 trial, which compared the TROP2-directed antibody drug conjugate against traditional chemotherapy.
Data demonstrated a statistically significant improvement in median overall survival, with patients receiving Datroway achieving 23.7 months compared to 18.7 months in the chemotherapy control arm.
Furthermore, the drug demonstrated a 43% reduction in the risk of disease progression or death.
Secondary efficacy endpoints also favored Datroway, which yielded an objective response rate of 62.5%, significantly outpacing the 29.3% observed in the chemotherapy cohort.
The safety profile remained consistent with previously documented studies.
Following these findings, the ESMO Clinical Practice Guidelines have classified Datroway as a Category IA first-line treatment, designating it as a preferred option for patients experiencing relapse within six months of adjuvant therapy. The treatment was also awarded a score of 4 out of 5 on the ESMO Magnitude of Clinical Benefit Scale.
Having gained U.S. approval in May 2026, Datroway is currently under regulatory review in Switzerland, Singapore, Canada, Australia, Japan, and China through the Project Orbis framework. AstraZeneca and Daiichi Sankyo remain in active collaboration regarding the global development and commercialization of the drug.
Industry analysts observe that this approval represents a significant transformation in the TNBC therapeutic landscape. The shift toward precision medicine creates a competitive divide between oncology providers: independent clinics with the operational agility to rapidly integrate new standards of care are expected to benefit from the clear Category IA classification, while larger hospital networks may face challenges due to rigid procurement and legacy treatment protocols.
From a strategic standpoint, the industry anticipates a rapid move away from standard chemotherapy in the metastatic setting as Datroway gains global traction.
With $4 billion in potential sales-related milestones attached to the AstraZeneca-Daiichi Sankyo partnership, the drug is positioned to become a foundational element of TNBC treatment.
Consequently, the sector is likely to see a re-evaluation of oncology supply chains, with market influence shifting toward providers capable of prioritizing the swift implementation of high-efficacy, target-specific therapeutics.